MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCL

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

Related Keywords

, Evolving Treatment Paradigm , Advanced Non , Small Cell Lung Cancer , Second Line , Non Small Cell Lung Cancer , Nsclc , Advanced Non Small Cell Lung Cancer , Advanced Nsclc , Nsclc Treatment , Egfr Mutant Lung Cancer , Egfr Mutated Lung Cancer , Second Line Treatment , Mariposa 2 ,